{"product_id":"thyroid-nodules-understanding-how-doctors-distinguish-benign-from-malignant-a-complete-patient-guide","title":"Thyroid Nodules: Understanding How Doctors Distinguish Benign From Malignant — A Complete Patient Guide","description":"\u003cp\u003eThyroid nodules are extremely common — found in up to 67% of adults on ultrasound — and while the vast majority are benign, about 7–15% are malignant. This evidence-based guide, written for general practitioners (GPs), walks through the key steps of evaluating a thyroid nodule: measuring thyroid-stimulating hormone (TSH), performing ultrasonography, and using fine-needle aspiration (FNA) when needed. The article also explains the updated 2015 American Thyroid Association (ATA) risk stratification system, how to manage incidentally discovered nodules, and special considerations for children and pregnant women. For patients, this means there is a clear, standardized pathway for determining whether a nodule is harmless or requires surgery.\u003c\/p\u003e\n\u003ch1\u003eThyroid Nodules: Understanding How Doctors Distinguish Benign From Malignant — A Complete Patient Guide\u003c\/h1\u003e\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-are-nodules\"\u003eWhat Are Thyroid Nodules?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#evaluation\"\u003eEvaluating a Thyroid Nodule: History and Physical Exam\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lab-tests\"\u003eLaboratory Tests: The Role of TSH and Other Blood Markers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#radionuclide\"\u003eRadionuclide Imaging: When Is It Used?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ultrasonography\"\u003eUltrasonography: The Imaging Gold Standard\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fna\"\u003eFine-Needle Aspiration: The Definitive Diagnostic Tool\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#management\"\u003eManagement: What Happens After the Results?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#incidentaloma\"\u003eIncidentalomas: Nodules Found by Chance\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pediatric\"\u003eThyroid Nodules in Children\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pregnancy\"\u003eThyroid Nodules During Pregnancy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Article\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMost thyroid nodules are benign; only 7–15% are malignant, so generalized panic is not warranted.\u003c\/li\u003e\n\u003cli\u003eEvaluation follows a clear pathway: TSH blood test, then ultrasound, then FNA if ultrasound features indicate risk.\u003c\/li\u003e\n\u003cli\u003eNot every nodule needs biopsy: size thresholds depend on ultrasound risk pattern, ranging from ≥1 cm to ≥2 cm.\u003c\/li\u003e\n\u003cli\u003eIncidental thyroid nodules found on CT, MRI, or PET require ultrasound assessment to determine malignancy risk.\u003c\/li\u003e\n\u003cli\u003eChildren with thyroid nodules have higher malignancy risk (26% in one large review), so more aggressive management is appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eThe widespread use of medical imaging — including CT scans, MRIs, and ultrasounds — has led to a dramatic increase in the detection of thyroid nodules. This is both good news and a challenge.\u003c\/p\u003e\n\u003cp\u003eThe challenge for doctors is that while the majority of nodules are benign (non-cancerous), the risk of malignancy (cancer) in an adult ranges from \u003cstrong\u003e7% to 15%\u003c\/strong\u003e. That means for every 100 adults with a thyroid nodule, roughly 7 to 15 will have cancer. General practitioners must therefore be skilled at evaluating these nodules and referring patients to specialists when appropriate.\u003c\/p\u003e\n\u003cp\u003eThis guide, published in the \u003cem\u003eAustralian Journal of General Practice\u003c\/em\u003e in November 2018, was written to bring GPs up to date on evidence-based management of thyroid nodules, with particular focus on neoplastic (tumor-forming) nodules and significant changes introduced in the \u003cstrong\u003e2015 American Thyroid Association (ATA) guidelines\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe stakes are high on both sides. Missing a cancer diagnosis can lead to significant harm, but over-investigating the many benign nodules creates an enormous economic burden on the healthcare system. The goal is a balanced, standardized approach.\u003c\/p\u003e\n\u003ch2 id=\"what-are-nodules\"\u003eWhat Are Thyroid Nodules?\u003c\/h2\u003e\n\u003cp\u003eThyroid nodules are discrete lesions (distinct abnormal growths) present within the thyroid gland — the butterfly-shaped gland in the front of your neck that regulates metabolism. They are radiologically distinct from the adjacent normal thyroid tissue.\u003c\/p\u003e\n\u003cp\u003eHere is how common they are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePalpable (feelable by hand) in \u003cstrong\u003e4–7% of the population\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eDetected using ultrasonography in up to \u003cstrong\u003e67% of adults\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eRisk of malignancy: approximately \u003cstrong\u003e7–15%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThyroid nodules come in several types, classified by their cellular makeup:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNon-neoplastic\u003c\/td\u003e\n\u003ctd\u003eHyperplastic, colloid, inflammatory, thyroid cysts*\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNeoplastic — Benign\u003c\/td\u003e\n\u003ctd\u003eFollicular adenoma\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003eNeoplastic — Malignant\u003c\/td\u003e\n\u003ctd\u003ePapillary, follicular, medullary, anaplastic, lymphoma, metastasis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp class=\"note\"\u003e*Thyroid cysts are nearly uniformly benign.\u003c\/p\u003e\n\u003cp\u003eThis classification matters because it drives the next steps in evaluation and treatment.\u003c\/p\u003e\n\u003ch2 id=\"evaluation\"\u003eEvaluating a Thyroid Nodule: History and Physical Exam\u003c\/h2\u003e\n\u003cp\u003eThyroid nodules can present in several ways. Most are simply a lump in the neck noticed by either the patient or the doctor, without any associated symptoms. Many others are found incidentally on imaging tests ordered for unrelated conditions, such as a CT scan of the chest or a carotid ultrasound.\u003c\/p\u003e\n\u003cp\u003eLarger nodules can cause compressive symptoms, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDyspnoea\u003c\/strong\u003e (shortness of breath)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlobus\u003c\/strong\u003e (a sensation of a lump in the throat)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDysphagia\u003c\/strong\u003e (difficulty swallowing)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAny symptom suggestive of invasion of nearby structures — especially \u003cstrong\u003edysphonia\u003c\/strong\u003e (hoarseness or voice changes) or dysphagia — should raise suspicion for an underlying malignancy and prompt urgent evaluation.\u003c\/p\u003e\n\u003ch3\u003eKey History Points\u003c\/h3\u003e\n\u003cp\u003eA thorough history is vital in formulating a complete risk assessment. The single most important historical factor is a \u003cstrong\u003ehistory of childhood head and neck irradiation\u003c\/strong\u003e (radiation therapy), which significantly increases the likelihood that a thyroid nodule is malignant.\u003c\/p\u003e\n\u003cp\u003eWhile the majority of thyroid malignancies are sporadic (occurring by chance), a number of familial (inherited) conditions can predispose a person to thyroid cancer, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple endocrine neoplasia type 2 (MEN2)\u003c\/strong\u003e — an inherited syndrome associated with medullary thyroid cancer\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFamilial nonmedullary thyroid cancer (FNMTC)\u003c\/strong\u003e — affects two or more first-degree relatives and can occur in isolation or as part of a syndrome\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFNMTC can also be part of broader genetic syndromes, including familial adenomatous polyposis (FAP), Cowden's syndrome, Gardner's syndrome, and Carney's complex type 1.\u003c\/p\u003e\n\u003ch3\u003ePhysical Examination\u003c\/h3\u003e\n\u003cp\u003eClinical examination should involve inspection and palpation (feeling) of the thyroid gland and examination of the cervical lymph nodes in the neck. The nodule itself should be assessed for three features:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\u003cstrong\u003eSize\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsistency\u003c\/strong\u003e (how firm or soft it feels)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMobility\u003c\/strong\u003e (whether it moves freely)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eWhen the patient swallows, the thyroid and any nodule should move in an upward direction — this is a normal finding. The presence of a \u003cstrong\u003efirm, fixed (immobile) nodule\u003c\/strong\u003e or \u003cstrong\u003eipsilateral cervical lymphadenopathy\u003c\/strong\u003e (enlarged lymph nodes on the same side of the neck) are late features suggestive of malignancy and should not delay further assessment.\u003c\/p\u003e\n\u003ch2 id=\"lab-tests\"\u003eLaboratory Tests: The Role of TSH and Other Blood Markers\u003c\/h2\u003e\n\u003cp\u003eA \u003cstrong\u003ethyroid-stimulating hormone (TSH)\u003c\/strong\u003e serum level should be obtained in \u003cem\u003eall\u003c\/em\u003e patients suspected of having a thyroid nodule on examination, or in whom one was incidentally discovered. TSH is the pituitary hormone that tells the thyroid to produce thyroid hormones — measuring it is the first screening blood test.\u003c\/p\u003e\n\u003cp\u003eHere is what the results mean:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNormal TSH (euthyroid)\u003c\/strong\u003e: This is the case for the majority of patients. The nodule is likely not producing excess hormone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSuppressed TSH\u003c\/strong\u003e: This indicates a \u003cstrong\u003ehyperfunctioning nodule\u003c\/strong\u003e — a nodule that is producing thyroid hormone on its own. If confirmed, such a nodule has an \u003cstrong\u003eexceedingly small risk of malignancy\u003c\/strong\u003e (less than 1%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients with suppressed TSH levels are best managed by an endocrinologist (a hormone specialist) for further evaluation, which typically includes a radionuclide scan.\u003c\/p\u003e\n\u003ch3\u003eTests That Should NOT Be Routinely Ordered\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSerum thyroglobulin levels\u003c\/strong\u003e: These are \u003cem\u003eneither sensitive nor specific\u003c\/em\u003e for the detection of thyroid cancer and should \u003cstrong\u003enot\u003c\/strong\u003e be ordered in the initial evaluation of thyroid nodules. (Thyroglobulin is a protein made by the thyroid, but blood levels do not reliably distinguish benign from malignant nodules.)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSerum calcitonin levels\u003c\/strong\u003e: These are expensive to obtain and should only be requested when a \u003cstrong\u003emedullary thyroid carcinoma\u003c\/strong\u003e is specifically suspected, since calcitonin is the tumor marker for this rare cancer type.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"radionuclide\"\u003eRadionuclide Imaging: When Is It Used?\u003c\/h2\u003e\n\u003cp\u003eThe 2015 ATA guidelines recommend that \u003cstrong\u003eonly patients with a TSH level below the normal range\u003c\/strong\u003e should undergo a radionuclide test. This test establishes whether there is an overactive gland or a hyperfunctioning (\"hot\") nodule that is producing excess thyroid hormone.\u003c\/p\u003e\n\u003cp\u003eTwo types of radionuclide tracers are available:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIodine-123 (¹²³I)\u003c\/strong\u003e — the recommended radionuclide in the ATA guidelines\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTechnetium-99m pertechnetate (⁹⁹ᵐTc)\u003c\/strong\u003e — more accessible, easier, faster, and less expensive to perform in Australia\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eA study directly comparing the results of these two types of scintiscans (nuclear medicine imaging) showed a \u003cstrong\u003ehigh degree of correlation\u003c\/strong\u003e, particularly when differentiating between \"hot\" (hyperfunctioning) and \"cold\" (non-functioning) nodules. In general practice, radionuclide scans should \u003cstrong\u003enot be routinely ordered\u003c\/strong\u003e to evaluate thyroid nodules unless indicated by a low TSH result, and \u003cstrong\u003e⁹⁹ᵐTc should be the imaging modality of choice\u003c\/strong\u003e when a scan is needed.\u003c\/p\u003e\n\u003ch2 id=\"ultrasonography\"\u003eUltrasonography: The Imaging Gold Standard\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eUltrasonography (ultrasound)\u003c\/strong\u003e is the imaging modality of choice for thyroid nodules. High-resolution ultrasound machines can detect nodules as small as \u003cstrong\u003e1–3 mm\u003c\/strong\u003e, with a sensitivity of approximately \u003cstrong\u003e95%\u003c\/strong\u003e — meaning it catches 95 out of 100 nodules present.\u003c\/p\u003e\n\u003cp\u003eWho should get an ultrasound?\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAll patients suspected of having a thyroid nodule or nodular goitre (an enlarged thyroid with nodules)\u003c\/li\u003e\n  \u003cli\u003eAll patients in whom a nodule has been incidentally detected on another imaging modality (CT, MRI, PET)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIt is recommended that the thyroid nodule is \u003cstrong\u003enot imaged in isolation\u003c\/strong\u003e — the entire thyroid gland and neck should be examined so that other nodules and lymph nodes are assessed simultaneously.\u003c\/p\u003e\n\u003ch3\u003eUltrasound Risk Stratification: The 2015 ATA System\u003c\/h3\u003e\n\u003cp\u003eThe ultrasound assessment provides valuable information regarding the size and sonographic (ultrasound) features of nodules, which form the basis for risk stratification and guidance on whether fine-needle aspiration (FNA) is needed.\u003c\/p\u003e\n\u003cp\u003eThe 2015 ATA guidelines categorize thyroid nodules into \u003cstrong\u003efive groups\u003c\/strong\u003e based on their sonographic pattern. Each category carries an estimated malignancy risk and a specific FNA recommendation:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n\u003cth\u003eNodule Classification\u003c\/th\u003e\n\u003cth\u003eUltrasound Features\u003c\/th\u003e\n\u003cth\u003eMalignancy Risk\u003c\/th\u003e\n\u003cth\u003eFNA Recommendation\u003c\/th\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eBenign\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCystic nodules with no solid component\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003eFNA not required\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eVery low suspicion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSpongiform or partially cystic nodules\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003ctd\u003eMonitor with observation; consider FNA for nodules ≥2 cm\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eLow suspicion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSolid isoechoic or hyperechoic solid nodule, OR partially cystic nodule with eccentric solid areas\u003c\/td\u003e\n\u003ctd\u003e5–10%\u003c\/td\u003e\n\u003ctd\u003eFNA recommended for nodules ≥1.5 cm\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eIntermediate suspicion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSolid hypoechoic nodule with smooth margins\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003ctd\u003eFNA recommended for nodules ≥1 cm\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eHigh suspicion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSolid hypoechoic nodule OR solid hypoechoic component of a partially cystic nodule, PLUS one or more of: irregular margins (infiltrative, microlobulated), microcalcifications, taller-than-wide shape, rim calcifications with small extrusive soft tissue component, evidence of extrathyroidal extension\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70–90%\u003c\/td\u003e\n\u003ctd\u003eFNA recommended for nodules ≥1 cm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eBecause ultrasound reports do not yet consistently contain this formal risk stratification, GPs should be aware that the sonographic features with the \u003cstrong\u003ehighest specificity for thyroid cancer\u003c\/strong\u003e include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrocalcifications\u003c\/strong\u003e (tiny calcium deposits visible on ultrasound)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIrregular margins\u003c\/strong\u003e (nodule borders that are not smooth)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTaller-than-wide shape\u003c\/strong\u003e (greater anteroposterior diameter than transverse diameter on an axial recumbent image)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf it is unclear from the ultrasound or the report whether an FNA is required, the patient should be referred to a specialist who manages thyroid nodules — commonly an endocrinologist.\u003c\/p\u003e\n\u003ch2 id=\"fna\"\u003eFine-Needle Aspiration: The Definitive Diagnostic Tool\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFine-needle aspiration (FNA)\u003c\/strong\u003e is a procedure in which a thin needle is inserted into the nodule (usually guided by ultrasound) to collect cells for microscopic examination. It is a valuable and safe tool that has dramatically reduced the need for unnecessary thyroidectomies (surgical removal of the thyroid).\u003c\/p\u003e\n\u003cp\u003eWhen considering only technically satisfactory specimens, the diagnostic accuracy of FNA when performed by an experienced operator is approximately \u003cstrong\u003e95%\u003c\/strong\u003e, although this figure depends on how each cytology (cell) category is used in the calculation.\u003c\/p\u003e\n\u003cp\u003eThe decision to perform FNA depends on the sonographic pattern and the size of the nodule, as detailed in Table 2 above. The key thresholds are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNodules with benign ultrasound features: no FNA needed\u003c\/li\u003e\n  \u003cli\u003eVery low suspicion nodules ≥2 cm: consider FNA\u003c\/li\u003e\n  \u003cli\u003eLow suspicion nodules ≥1.5 cm: FNA recommended\u003c\/li\u003e\n  \u003cli\u003eIntermediate suspicion nodules ≥1 cm: FNA recommended\u003c\/li\u003e\n  \u003cli\u003eHigh suspicion nodules ≥1 cm: FNA recommended\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eThe Bethesda Classification System\u003c\/h3\u003e\n\u003cp\u003eA major update is that \u003cstrong\u003eall cytology results should now be reported using the Bethesda system\u003c\/strong\u003e for classification of thyroid nodules, which aligns with the Thy classification system adopted by the Royal College of Pathologists in the UK.\u003c\/p\u003e\n\u003cp\u003eThe Bethesda system categorizes FNA results into six diagnostic categories, each with an associated malignancy risk and a recommended management plan:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda I — Non-diagnostic\/unsatisfactory\u003c\/strong\u003e: Repeat FNA or refer for further assessment\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda II — Benign\u003c\/strong\u003e: Malignancy risk ~0–3%; monitor with clinical follow-up\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda III — Atypia of undetermined significance\/follicular lesion of undetermined significance (AUS\/FLUS)\u003c\/strong\u003e: Malignancy risk ~5–15%; refer to endocrinologist\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda IV — Follicular neoplasm\/suspicious for follicular neoplasm (FN\/SFN)\u003c\/strong\u003e: Malignancy risk ~15–30%; refer to endocrinologist\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda V — Suspicious for malignancy\u003c\/strong\u003e: Malignancy risk ~60–75%; refer to high-volume thyroid surgeon\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda VI — Malignant\u003c\/strong\u003e: Malignancy risk ~97–99%; refer to high-volume thyroid surgeon\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"management\"\u003eManagement: What Happens After the Results?\u003c\/h2\u003e\n\u003cp\u003eThe primary goal of the GP is to differentiate between a benign and a malignant nodule. Cytology (the FNA cell analysis) plays a key part in determining the most appropriate management and follow-up.\u003c\/p\u003e\n\u003ch3\u003eBenign Cytology\u003c\/h3\u003e\n\u003cp\u003eThe majority of thyroid nodules encountered in general practice will have \u003cstrong\u003ebenign cytology\u003c\/strong\u003e. These can be monitored with a repeat ultrasound scan at a time interval determined by the sonographic features rather than treated surgically.\u003c\/p\u003e\n\u003ch3\u003eNon-Diagnostic Results\u003c\/h3\u003e\n\u003cp\u003eA non-diagnostic or unsatisfactory FNA test should have a \u003cstrong\u003erepeat ultrasound-guided FNA\u003c\/strong\u003e or be referred on for further assessment.\u003c\/p\u003e\n\u003ch3\u003eIndeterminate or Suspicious Results\u003c\/h3\u003e\n\u003cp\u003eWith the exception of benign cytology, \u003cstrong\u003eall other results should be referred\u003c\/strong\u003e to an endocrinologist or thyroid surgeon for further assessment. Management of indeterminate cytology can be complex. Many endocrinologists are now experienced in interpreting and performing thyroid ultrasonography and FNA and can offer expertise in interpreting indeterminate results.\u003c\/p\u003e\n\u003cp\u003eAny malignancy or suspected malignancy should be referred \u003cstrong\u003edirectly to a high-volume thyroid surgeon\u003c\/strong\u003e — that is, a surgeon who performs a large number of thyroid operations and therefore has better outcomes.\u003c\/p\u003e\n\u003ch3\u003eFollow-Up Timing for Nodules That Don't Undergo FNA\u003c\/h3\u003e\n\u003cp\u003eA significant proportion of thyroid nodules do not meet FNA criteria (because they are small or have reassuring ultrasound features). For these, ultrasound features guide follow-up:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHighly suspicious nodules\u003c\/strong\u003e: repeat ultrasonography within \u003cstrong\u003e6–12 months\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-risk and intermediate-risk nodules\u003c\/strong\u003e: repeat ultrasonography within \u003cstrong\u003e12–24 months\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVery low risk nodules \u0026lt;1 cm\u003c\/strong\u003e: these have been shown to grow very little over five years and \u003cstrong\u003edo not require routine ultrasonographic follow-up\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"incidentaloma\"\u003eIncidentalomas: Nodules Found by Chance\u003c\/h2\u003e\n\u003cp\u003eAn \u003cstrong\u003eincidentaloma\u003c\/strong\u003e is a non-palpable (cannot be felt), asymptomatic thyroid nodule detected via imaging performed for other reasons. Importantly, an incidentaloma has the \u003cstrong\u003esame malignancy risk as a palpable nodule\u003c\/strong\u003e — so it cannot be dismissed simply because it was found by accident.\u003c\/p\u003e\n\u003cp\u003eKey points about incidentalomas:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCT and MRI scans\u003c\/strong\u003e cannot give precise structural details of the thyroid. Nodules detected using these techniques should be assessed further with ultrasonography.\u003c\/li\u003e\n  \u003cli\u003eA large proportion of incidentalomas will be \u003cstrong\u003eunder 1 cm\u003c\/strong\u003e. It is important they are managed according to the guidelines to avoid over-investigation and unnecessary procedures.\u003c\/li\u003e\n  \u003cli\u003eApproximately \u003cstrong\u003e1–2% of FDG-PET scans\u003c\/strong\u003e (a type of functional imaging used mainly in cancer staging) show focal thyroid uptake.\u003c\/li\u003e\n  \u003cli\u003eA recent meta-analysis showed that \u003cstrong\u003e35% of those focal PET-positive nodules were malignant\u003c\/strong\u003e — a strikingly high rate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBecause of this increased risk of malignancy, the new recommendation is for patients to undergo \u003cstrong\u003eultrasound-based FNA for all focal nodules \u0026gt;1 cm detected on FDG-PET\u003c\/strong\u003e. Nodules smaller than 1 cm that do not meet FNA criteria should be monitored.\u003c\/p\u003e\n\u003ch2 id=\"pediatric\"\u003eThyroid Nodules in Children\u003c\/h2\u003e\n\u003cp\u003eThyroid nodules are less common in children, but when they do occur, the risk of cancer is much higher than in adults.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIncidence of palpable paediatric thyroid nodules: approximately \u003cstrong\u003e1.8–5.1%\u003c\/strong\u003e with the use of ultrasonography.\u003c\/li\u003e\n  \u003cli\u003eIn a review of \u003cstrong\u003e1,134 children\u003c\/strong\u003e, the overall malignancy rate was \u003cstrong\u003e26%\u003c\/strong\u003e — compared with only \u003cstrong\u003e5–10% in adults\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe ATA guidelines suggest paediatric nodules should be evaluated in a similar manner to adult nodules, with some important exceptions:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFNA size thresholds differ\u003c\/strong\u003e: Because children and their thyroid glands are proportionally smaller, FNA should be based on clinical context and sonographic features rather than the absolute size of the nodule.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIndeterminate cytology is treated more aggressively\u003c\/strong\u003e: In cases of indeterminate cytology, because of the increased risk of malignancy, referral to a thyroid surgeon for \u003cstrong\u003ehemithyroidectomy\u003c\/strong\u003e (removal of half the thyroid) is recommended \u003cem\u003eover\u003c\/em\u003e a repeated FNA.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThis reflects the principle that \"children are not small adults\" — their disease behaves differently and requires a more proactive surgical approach.\u003c\/p\u003e\n\u003ch2 id=\"pregnancy\"\u003eThyroid Nodules During Pregnancy\u003c\/h2\u003e\n\u003cp\u003eNodules detected during pregnancy should be assessed on the basis of serum TSH levels:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIf the TSH level is \u003cstrong\u003enormal or elevated\u003c\/strong\u003e, FNA should be performed.\u003c\/li\u003e\n  \u003cli\u003eThe good news: \u003cstrong\u003eThyroid cancer does not behave more aggressively during pregnancy\u003c\/strong\u003e, and age-matched non-pregnant women have a similarly excellent prognosis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients with nodules detected during pregnancy should be referred to a thyroid surgeon for discussion regarding \u003cstrong\u003edelaying surgery or timing surgery\u003c\/strong\u003e to minimize fetal and patient risks. In many cases, surgery can be safely postponed until after delivery.\u003c\/p\u003e\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\u003cp\u003eSo, what does all of this mean for you as a patient? Here are the key takeaways:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMost nodules are benign\u003c\/strong\u003e — only 7–15% are malignant, so try not to panic when a nodule is found.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYour doctor will follow a clear, evidence-based pathway\u003c\/strong\u003e: blood test for TSH first, then ultrasound, then FNA if the ultrasound features warrant it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot every nodule needs a biopsy\u003c\/strong\u003e — small nodules with reassuring ultrasound features can be safely monitored. The ultrasound pattern determines the threshold for FNA (size cutoffs range from ≥1 cm for high-risk patterns to ≥2 cm for very low-risk patterns).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadionuclide scans are reserved for patients with low TSH\u003c\/strong\u003e — they are not part of routine evaluation for everyone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have a concerning result, you will be referred quickly\u003c\/strong\u003e — to an endocrinologist for indeterminate results, and directly to a high-volume thyroid surgeon for confirmed or suspected malignancy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf your nodule was found by accident on a CT or MRI, you need a follow-up ultrasound\u003c\/strong\u003e to properly characterize it.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you had childhood radiation to the head or neck, tell your doctor\u003c\/strong\u003e — this significantly raises your risk and may change management.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChildren with nodules are a special case\u003c\/strong\u003e — the cancer risk is much higher (26% in one large review), so a more aggressive approach is justified.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePregnancy is not a reason to delay evaluation\u003c\/strong\u003e — but surgery can often be safely postponed, and outcomes are excellent.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2 id=\"limitations\"\u003eLimitations of This Article\u003c\/h2\u003e\n\u003cp\u003eThis is a clinical review article, not a new research study. As such, it summarizes existing evidence and guidelines rather than presenting new patient data. Some limitations to be aware of:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe malignancy risk estimates (e.g., 7–15% overall, 26% in children) come from various studies with different populations and time periods, so individual risk may vary.\u003c\/li\u003e\n  \u003cli\u003eThe 95% diagnostic accuracy of FNA depends heavily on the experience of the operator and the cytology category used in the calculation.\u003c\/li\u003e\n  \u003cli\u003eThe article reflects the 2015 ATA guidelines; newer updates may have refined some recommendations since publication.\u003c\/li\u003e\n  \u003cli\u003eThis article is written for Australian general practice; availability of specific tests (such as technetium-99m scans) may differ in other countries.\u003c\/li\u003e\n  \u003cli\u003eIndividual patient decisions should always be made in consultation with your own doctor, who has access to your full medical history, imaging, and test results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a thyroid nodule, and how common are they?\u003c\/h3\u003e\n\u003cp\u003eThyroid nodules are distinct abnormal growths inside the thyroid gland, a butterfly-shaped gland in your neck. They are very common: found in up to 67% of adults on ultrasound and felt by hand in 4–7%. While most nodules are benign, about 7–15% are malignant, meaning they contain cancer.\u003c\/p\u003e\n\u003ch3\u003eHow do doctors tell if a thyroid nodule is benign or malignant?\u003c\/h3\u003e\n\u003cp\u003eDoctors follow a standard pathway. First, they test your blood for thyroid-stimulating hormone (TSH). Next, you get an ultrasound to examine the nodule’s size and features. If ultrasound features suggest risk, a fine-needle aspiration (FNA) is done to collect cells. Most nodules are benign, and only 7–15% are malignant.\u003c\/p\u003e\n\u003ch3\u003eDo all thyroid nodules need a biopsy?\u003c\/h3\u003e\n\u003cp\u003eNo. The ultrasound pattern determines whether FNA is needed. Benign-looking nodules may need no biopsy. For very low suspicion nodules, FNA is considered if they are 2 cm or larger. Low suspicion nodules need FNA at 1.5 cm or larger, while intermediate and high suspicion nodules need FNA at 1 cm or larger.\u003c\/p\u003e\n\u003ch3\u003eWhat does a low TSH level mean for my thyroid nodule?\u003c\/h3\u003e\n\u003cp\u003eA low TSH suggests your nodule may be hyperfunctioning, meaning it produces thyroid hormone on its own. In this case, the risk of cancer is very small, less than 1%. Your doctor will likely refer you to an endocrinologist and may order a radionuclide scan to confirm the nodule is overactive.\u003c\/p\u003e\n\u003ch3\u003eWhat is fine-needle aspiration (FNA) for a thyroid nodule?\u003c\/h3\u003e\n\u003cp\u003eFNA is a safe procedure where a thin needle is inserted into the nodule, usually guided by ultrasound, to collect cells for examination. When done by an experienced operator and with satisfactory samples, its diagnostic accuracy is about 95%. It helps distinguish benign from malignant nodules and reduces unnecessary surgeries.\u003c\/p\u003e\n\u003ch3\u003eMy child has a thyroid nodule. Is the risk of cancer higher than in adults?\u003c\/h3\u003e\n\u003cp\u003eYes. Although thyroid nodules are less common in children, when they occur, the cancer risk is higher: one review of 1,134 children found a 26% malignancy rate, compared with 5–10% in adults. Therefore, children are managed more aggressively, and size thresholds for FNA may differ.\u003c\/p\u003e\n\u003ch3\u003eMy thyroid nodule biopsy came back as indeterminate or suspicious — should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eMost thyroid nodules are benign, but 7–15% are malignant. If your biopsy is indeterminate or suspicious, the recommended next step varies: benign results can be monitored, while atypical (Bethesda III), follicular (Bethesda IV), suspicious, or malignant results are usually referred to an endocrinologist or high-volume thyroid surgeon. Because management of indeterminate cytology is complex, a second opinion can help you confirm whether surgery is truly necessary or whether watchful monitoring is safe. Reviewing your ultrasound images and biopsy slides by an independent expert may clarify your risk. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e RACGP - Differentiating between benign and malignant thyroid nodules\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Stuart Bailey, Benjamin Wallwork\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eAustralian Journal of General Practice\u003c\/em\u003e (AJGP), Volume 47, Issue 11, November 2018\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.31128\/AJGP-03-18-4518\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublisher:\u003c\/strong\u003e Royal Australian College of General Practitioners (RACGP)\u003c\/p\u003e\n\u003cp class=\"note\"\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your healthcare provider. Always discuss your specific situation with your doctor.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47471115796636,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ja\/products\/thyroid-nodules-understanding-how-doctors-distinguish-benign-from-malignant-a-complete-patient-guide","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}